Literature DB >> 25549280

Small molecule inhibitors of bromodomain-acetyl-lysine interactions.

Michael Brand1, Angelina R Measures, Angelina M Measures, Brian G Wilson, Wilian A Cortopassi, Rikki Alexander, Matthias Höss, David S Hewings, Timothy P C Rooney, Robert S Paton, Stuart J Conway.   

Abstract

Bromodomains are protein modules that bind to acetylated lysine residues. Their interaction with histone proteins suggests that they function as "readers" of histone lysine acetylation, a component of the proposed "histone code". Bromodomain-containing proteins are often found as components of larger protein complexes with roles in fundamental cellular process including transcription. The publication of two potent ligands for the BET bromodomains in 2010 demonstrated that small molecules can inhibit the bromodomain-acetyl-lysine protein-protein interaction. These molecules display strong phenotypic effects in a number of cell lines and affect a range of cancers in vivo. This work stimulated intense interest in developing further ligands for the BET bromodomains and the design of ligands for non-BET bromodomains. Here we review the recent progress in the field with particular attention paid to ligand design, the assays employed in early ligand discovery, and the use of computational approaches to inform ligand design.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25549280     DOI: 10.1021/cb500996u

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  47 in total

1.  Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.

Authors:  Brandon L Crowe; Ross C Larue; Chunhua Yuan; Sonja Hess; Mamuka Kvaratskhelia; Mark P Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

2.  BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.

Authors:  Lijia Chen; Jeremy L Yap; Makoto Yoshioka; Maryanna E Lanning; Rachel N Fountain; Mithun Raje; Jacob A Scheenstra; Jeffrey W Strovel; Steven Fletcher
Journal:  ACS Med Chem Lett       Date:  2015-05-18       Impact factor: 4.345

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

4.  GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2).

Authors:  Terry D Crawford; James E Audia; Steve Bellon; Daniel J Burdick; Archana Bommi-Reddy; Alexandre Côté; Richard T Cummings; Martin Duplessis; E Megan Flynn; Michael Hewitt; Hon-Ren Huang; Hariharan Jayaram; Ying Jiang; Shivangi Joshi; James R Kiefer; Jeremy Murray; Christopher G Nasveschuk; Arianne Neiss; Eneida Pardo; F Anthony Romero; Peter Sandy; Robert J Sims; Yong Tang; Alexander M Taylor; Vickie Tsui; Jian Wang; Shumei Wang; Yongyun Wang; Zhaowu Xu; Laura Zawadzke; Xiaoqin Zhu; Brian K Albrecht; Steven R Magnuson; Andrea G Cochran
Journal:  ACS Med Chem Lett       Date:  2017-06-01       Impact factor: 4.345

5.  Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.

Authors:  Beth E Zucconi; Jessica L Makofske; David J Meyers; Yousang Hwang; Mingxuan Wu; Mitzi I Kuroda; Philip A Cole
Journal:  Biochemistry       Date:  2019-04-11       Impact factor: 3.162

Review 6.  BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.

Authors:  Dequina A Nicholas; Guillaume Andrieu; Katherine J Strissel; Barbara S Nikolajczyk; Gerald V Denis
Journal:  Cell Mol Life Sci       Date:  2016-08-04       Impact factor: 9.261

7.  Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.

Authors:  Angela S Carlson; Huarui Cui; Anand Divakaran; Jorden A Johnson; Ryan M Brunner; William C K Pomerantz; Joseph J Topczewski
Journal:  ACS Med Chem Lett       Date:  2019-08-02       Impact factor: 4.345

8.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.

Authors:  Natalie H Theodoulou; Paul Bamborough; Andrew J Bannister; Isabelle Becher; Rino A Bit; Ka Hing Che; Chun-wa Chung; Antje Dittmann; Gerard Drewes; David H Drewry; Laurie Gordon; Paola Grandi; Melanie Leveridge; Matthew Lindon; Anne-Marie Michon; Judit Molnar; Samuel C Robson; Nicholas C O Tomkinson; Tony Kouzarides; Rab K Prinjha; Philip G Humphreys
Journal:  J Med Chem       Date:  2015-04-30       Impact factor: 7.446

9.  Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities.

Authors:  Li Liu; Yongxia Zhu; Zhihao Liu; Tinghong Ye; Weiqiong Zuo; Cuiting Peng; Kunjie Xiao; Ningyu Wang; Luoting Yu
Journal:  Mol Divers       Date:  2016-11-17       Impact factor: 2.943

10.  The Bromodomain: A New Target in Emerging Epigenetic Medicine.

Authors:  Steven G Smith; Ming-Ming Zhou
Journal:  ACS Chem Biol       Date:  2015-12-03       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.